Forbion Capital Partners Archives

News and Trends 19 Apr 2023

Forbion raises €1.35B to invest in life science companies

European life sciences venture capital firm Forbion has raised €1.35 billion ($1.5 billion) for its two newest funds, bringing the total of funds under management to €3 billion ($3.3 billion). Both funds exceeded the original target sizes and represent Forbion’s largest fundraising to date. The final close of the Forbion Ventures Fund VI has reached […]

April 19, 2023 - 3 minutesmins - By Jim Cornall

Opinion 28 Feb 2023

Life changing treatments for rare disease – a beacon of hope

By Sander Slootweg, managing partner, Forbion More than 300 million people around the globe are affected by a rare disease. This number does not even take into account the impact on these individuals’ support units that includes family, friends and caregivers. A rare disease is defined as a disease that affects no more than 1 […]

February 28, 2023 - 6 minutesmins - By External Contributor

News and Trends 17 Jun 2022

Beyond Biotech podcast 1: Forbion, OMass, PharNext

It’s the first official Beyond Biotech podcast! And this week, we have three interviews. We talked with Ros Deegan, CEO of OMass; David Solomon, CEO of PharNext; and two people from Forbion, Sander Slootweg, managing partner, and Dirk Mertens, general partner. Forbion European life sciences venture capital firm Forbion, has announced the first €470M ($500M) […]

June 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

New Forbion life sciences fund hits €470M

European life sciences venture capital firm Forbion, has announced the first €470M ($500M) close of its Forbion Growth Opportunities Fund II. The fund will focus on investing in late-stage European life sciences companies. The new fund has attracted several new institutional investors, including pension funds PME and PMT, the Ewing Marion Kauffman Foundation and Reggeborgh, […]

June 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Mar 2022

Biotech Stocks in “Total Eclipse” as Financial Pressures Mount

More than a year after biotech stock indices peaked, the markets are worse than ever. Meanwhile, rumors of an impending wave of opportunistic biotech acquisitions are yet to materialize. In February of last year, biotech stocks across Europe and the US saw the end of a pandemic-fuelled growth spurt. Since then, the stock growth of […]

March 15, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 10 Dec 2021

European Biotech Investors Cap Off Record Year in Fundraising

The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Merck’s venture capital arm M Ventures raise impressive funds to speed up life sciences innovation. This year is set to break records in terms of the money flowing into institutional life science investors. With 2021 not even finished, […]

December 10, 2021 - 4 minutesmins - By Jonathan Smith

News and Trends 13 Jul 2020

Forbion Raises €185M to Fuel Late-Stage European Biotechs

The Dutch life sciences venture capital firm Forbion has bagged €185M in the first closing of a fund aimed at investing in late-stage European biotech companies, which often struggle to raise capital. The main mission of Forbion’s fund — named the Growth Opportunities Fund — is to invest in European life sciences companies raising their […]

July 13, 2020 - 3 minutesmins - By David Wilson

Inflazome Forbion inflammatory disease macrophage

More News! 19 Nov 2018

Anti-Inflammatory Treatments Get €40M Boost in Series B

A Series B funding round has whipped up €40M for the Irish company Inflazome. This money will help to fund clinical trials for anti-inflammatory treatments targeting conditions such as Alzheimer’s and Parkinson’s disease. “We are extremely excited about this opportunity, which is such a large funding round in a European company,” Marco Boorsma, General Partner […]

November 19, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Oct 2018

Update: Forbion’s Life Science Fund Tops Goal by €90M

Update: The European venture capital firm Forbion closed fundraising for it’s fourth life sciences fund at €360M, a much greater amount than the anticipated €250M. The oversubscribed fund is great news for European medical biotech companies, which will be a strong focus for the fund, and shows that there is a strong interest in the […]

October 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Apr 2018

British Biotech Raises £29M Round to Fight Lung Disease

Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for respiratory diseases into clinical development. Enterprise Therapeutics, a British biotech, has raised £29M (€33M) in Series B from several investors including Forbion, one of the most active European life science VCs. In Enterprise, Forbion has found a replacement in its portfolio for the Dutch […]

April 12, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 12 Dec 2017

New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH

NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a disease with no treatment and a huge market. With a €25M investment in Series A, NorthSea Therapeutics is all set to start Phase II trials in nonalcoholic steatohepatitis (NASH) and take on a very profitable market. The fundraising was led by Forbion […]

December 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 20 Jun 2017

“We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh

A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can effectively fight cancer. “I think right now we’re at a second revolution in cancer therapy, which surprisingly is not necessarily driven by technology but perspective, and how we look at cancer,” said Masoud Tavazoie, CEO of Rgenix. His company, based in New York, […]

June 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us